G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

26 июл 2023 09:00:31 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 июл 2023 16:15:03 Источник Nasdaq GlobeNewswire

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

04 июн 2023 07:13:44 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 июн 2023 16:40:59 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

22 май 2023 16:45:22 Источник Nasdaq GlobeNewswire

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

16 май 2023 07:30:11 Источник Nasdaq GlobeNewswire

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

10 май 2023 07:31:04 Источник Nasdaq GlobeNewswire

G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights

03 май 2023 06:30:55 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 май 2023 17:00:50 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

26 апр 2023 12:45:27 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

11 апр 2023 12:30:49 Источник Nasdaq GlobeNewswire

G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

01 мар 2023 06:30:27 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

28 фев 2023 14:10:49 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

22 фев 2023 10:00:17 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

13 фев 2023 06:00:38 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 фев 2023 16:46:01 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

11 янв 2023 07:00:47 Источник Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

09 янв 2023 06:30:31 Источник Nasdaq GlobeNewswire

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

04 янв 2023 06:30:12 Источник Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference

03 янв 2023 14:00:27 Источник Nasdaq GlobeNewswire